Intervention Clinical Trials Program

Intervention Clinical Trials Program

The Intervention Clinical Trials Program research team seeks better medication options to treat schizophrenia symptoms and mitigate the medical problems associated with existing medications.

Contact us 617-912-7800

Overview

The Intervention Clinical Trials Program has three primary research objectives:

Develop new medications to treat unresponsive symptoms

We research new medications and treatments to treat psychosis (hallucinations, delusions and disorganization), cognition (memory and attention) and negative symptoms (apathy, social withdrawal and loss of emotional expressiveness). The development of new treatments is guided by new findings in genetics and neuroimaging.

Improve existing medications

We seek to improve existing options through such strategies as combining medication, optimizing dosing and improving compliance.

Mitigate side effects and medical complications associated with these medications

We have made groundbreaking progress in understanding the mechanisms by which certain antipsychotics cause weight gain and may increase the risk for diabetes. We are looking at experimental alternatives that could prevent these side effects.

We also investigate how certain medications elevate prolactin and the long-term health consequences.

Group Members

Research Projects

To learn more about ongoing clinical trials, please call 617-912-7864 to talk with one of our research coordinators.

Publications

Contact

Contact Us

Intervention Clinical Trials Program

25 Staniford Street Boston, 02114
  • Phone: 617-912-7800
  • Fax: 617-723-3919

Contact us 617-912-7800

Back to Top